Harvard Bioscience, Inc. (HBIO) Stock Competitors & Peer Comparison
See (HBIO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HBIO | $6.20 | -4.32% | 27.9M | -2.88 | -$2.15 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.31% |
| BDX | $151.16 | +1.07% | 54.8B | 26.35 | $5.74 | +2.31% |
| ALC | $66.81 | +0.35% | 32.6B | 40.00 | $1.67 | +0.54% |
| MDLN | $33.61 | -2.44% | 28.4B | 29.48 | $1.14 | N/A |
| WST | $314.50 | -0.89% | 22.2B | 42.00 | $7.49 | +0.28% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.31% |
| COO | $67.34 | +8.58% | 13.1B | 33.50 | $2.01 | N/A |
| BAX | $19.38 | +0.16% | 10B | -10.14 | -$1.91 | +1.03% |
Stock Comparison
HBIO vs BDXA Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, HBIO is priced at $6.20, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas BDXA's P/E ratio is 21.44. In terms of profitability, HBIO's ROE is -0.73%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, HBIO is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check BDXA's competition here
HBIO vs BDX Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, BDX has a market cap of 54.8B. Regarding current trading prices, HBIO is priced at $6.20, while BDX trades at $151.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas BDX's P/E ratio is 26.35. In terms of profitability, HBIO's ROE is -0.73%, compared to BDX's ROE of +0.05%. Regarding short-term risk, HBIO is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check BDX's competition here
HBIO vs ALC Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ALC has a market cap of 32.6B. Regarding current trading prices, HBIO is priced at $6.20, while ALC trades at $66.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ALC's P/E ratio is 40.00. In terms of profitability, HBIO's ROE is -0.73%, compared to ALC's ROE of +0.04%. Regarding short-term risk, HBIO is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ALC's competition here
HBIO vs MDLN Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, MDLN has a market cap of 28.4B. Regarding current trading prices, HBIO is priced at $6.20, while MDLN trades at $33.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas MDLN's P/E ratio is 29.48. In terms of profitability, HBIO's ROE is -0.73%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, HBIO is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check MDLN's competition here
HBIO vs WST Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, WST has a market cap of 22.2B. Regarding current trading prices, HBIO is priced at $6.20, while WST trades at $314.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas WST's P/E ratio is 42.00. In terms of profitability, HBIO's ROE is -0.73%, compared to WST's ROE of +0.18%. Regarding short-term risk, HBIO is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check WST's competition here
HBIO vs HOLX Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, HBIO is priced at $6.20, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas HOLX's P/E ratio is 31.54. In terms of profitability, HBIO's ROE is -0.73%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, HBIO is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check HOLX's competition here
HBIO vs BDXB Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, HBIO is priced at $6.20, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas BDXB's P/E ratio is 7.60. In terms of profitability, HBIO's ROE is -0.73%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, HBIO is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check BDXB's competition here
HBIO vs COO Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, COO has a market cap of 13.1B. Regarding current trading prices, HBIO is priced at $6.20, while COO trades at $67.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas COO's P/E ratio is 33.50. In terms of profitability, HBIO's ROE is -0.73%, compared to COO's ROE of +0.03%. Regarding short-term risk, HBIO is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check COO's competition here
HBIO vs BAX Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, BAX has a market cap of 10B. Regarding current trading prices, HBIO is priced at $6.20, while BAX trades at $19.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas BAX's P/E ratio is -10.14. In terms of profitability, HBIO's ROE is -0.73%, compared to BAX's ROE of -0.16%. Regarding short-term risk, HBIO is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check BAX's competition here
HBIO vs ATR Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ATR has a market cap of 7.2B. Regarding current trading prices, HBIO is priced at $6.20, while ATR trades at $113.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ATR's P/E ratio is 19.42. In terms of profitability, HBIO's ROE is -0.73%, compared to ATR's ROE of +0.14%. Regarding short-term risk, HBIO is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ATR's competition here
HBIO vs RGEN Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, RGEN has a market cap of 6.9B. Regarding current trading prices, HBIO is priced at $6.20, while RGEN trades at $122.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas RGEN's P/E ratio is 134.41. In terms of profitability, HBIO's ROE is -0.73%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, HBIO is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check RGEN's competition here
HBIO vs AVTR Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, AVTR has a market cap of 6.3B. Regarding current trading prices, HBIO is priced at $6.20, while AVTR trades at $9.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas AVTR's P/E ratio is -11.30. In terms of profitability, HBIO's ROE is -0.73%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, HBIO is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check AVTR's competition here
HBIO vs TFX Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, HBIO is priced at $6.20, while TFX trades at $129.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas TFX's P/E ratio is 2164.33. In terms of profitability, HBIO's ROE is -0.73%, compared to TFX's ROE of -0.28%. Regarding short-term risk, HBIO is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check TFX's competition here
HBIO vs BLCO Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, BLCO has a market cap of 5.5B. Regarding current trading prices, HBIO is priced at $6.20, while BLCO trades at $15.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas BLCO's P/E ratio is -24.95. In terms of profitability, HBIO's ROE is -0.73%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, HBIO is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check BLCO's competition here
HBIO vs STVN Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, STVN has a market cap of 5.1B. Regarding current trading prices, HBIO is priced at $6.20, while STVN trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas STVN's P/E ratio is 31.39. In terms of profitability, HBIO's ROE is -0.73%, compared to STVN's ROE of +0.10%. Regarding short-term risk, HBIO is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check STVN's competition here
HBIO vs MMSI Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, MMSI has a market cap of 3.8B. Regarding current trading prices, HBIO is priced at $6.20, while MMSI trades at $64.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas MMSI's P/E ratio is 27.79. In terms of profitability, HBIO's ROE is -0.73%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, HBIO is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check MMSI's competition here
HBIO vs ICUI Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ICUI has a market cap of 3.4B. Regarding current trading prices, HBIO is priced at $6.20, while ICUI trades at $136.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ICUI's P/E ratio is 73.45. In terms of profitability, HBIO's ROE is -0.73%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, HBIO is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ICUI's competition here
HBIO vs HAE Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, HAE has a market cap of 3.2B. Regarding current trading prices, HBIO is priced at $6.20, while HAE trades at $71.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas HAE's P/E ratio is 34.79. In terms of profitability, HBIO's ROE is -0.73%, compared to HAE's ROE of +0.11%. Regarding short-term risk, HBIO is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check HAE's competition here
HBIO vs WRBY Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, WRBY has a market cap of 2.8B. Regarding current trading prices, HBIO is priced at $6.20, while WRBY trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas WRBY's P/E ratio is 2272.00. In terms of profitability, HBIO's ROE is -0.73%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, HBIO is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check WRBY's competition here
HBIO vs LMAT Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, HBIO is priced at $6.20, while LMAT trades at $94.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas LMAT's P/E ratio is 34.74. In terms of profitability, HBIO's ROE is -0.73%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, HBIO is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check LMAT's competition here
HBIO vs XRAY Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, HBIO is priced at $6.20, while XRAY trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas XRAY's P/E ratio is -3.17. In terms of profitability, HBIO's ROE is -0.73%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, HBIO is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check XRAY's competition here
HBIO vs NVCR Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, HBIO is priced at $6.20, while NVCR trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas NVCR's P/E ratio is -11.22. In terms of profitability, HBIO's ROE is -0.73%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, HBIO is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check NVCR's competition here
HBIO vs PLSE Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, PLSE has a market cap of 1.8B. Regarding current trading prices, HBIO is priced at $6.20, while PLSE trades at $25.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas PLSE's P/E ratio is -23.03. In terms of profitability, HBIO's ROE is -0.73%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, HBIO is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check PLSE's competition here
HBIO vs STAA Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, STAA has a market cap of 1.5B. Regarding current trading prices, HBIO is priced at $6.20, while STAA trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas STAA's P/E ratio is -71.40. In terms of profitability, HBIO's ROE is -0.73%, compared to STAA's ROE of -0.06%. Regarding short-term risk, HBIO is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check STAA's competition here
HBIO vs ATRC Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, HBIO is priced at $6.20, while ATRC trades at $27.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ATRC's P/E ratio is -271.00. In terms of profitability, HBIO's ROE is -0.73%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, HBIO is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ATRC's competition here
HBIO vs BLFS Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, HBIO is priced at $6.20, while BLFS trades at $26.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas BLFS's P/E ratio is -111.04. In terms of profitability, HBIO's ROE is -0.73%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, HBIO is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check BLFS's competition here
HBIO vs KMTS Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, HBIO is priced at $6.20, while KMTS trades at $19.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas KMTS's P/E ratio is -3.55. In terms of profitability, HBIO's ROE is -0.73%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, HBIO is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check KMTS's competition here
HBIO vs AZTA Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, AZTA has a market cap of 1B. Regarding current trading prices, HBIO is priced at $6.20, while AZTA trades at $22.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas AZTA's P/E ratio is -9.41. In terms of profitability, HBIO's ROE is -0.73%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, HBIO is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check AZTA's competition here
HBIO vs NNNN Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, NNNN has a market cap of 1B. Regarding current trading prices, HBIO is priced at $6.20, while NNNN trades at $22.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas NNNN's P/E ratio is 153.27. In terms of profitability, HBIO's ROE is -0.73%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, HBIO is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check NNNN's competition here
HBIO vs QDEL Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, QDEL has a market cap of 975.8M. Regarding current trading prices, HBIO is priced at $6.20, while QDEL trades at $14.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas QDEL's P/E ratio is -0.80. In terms of profitability, HBIO's ROE is -0.73%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, HBIO is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check QDEL's competition here
HBIO vs ATRI Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, HBIO is priced at $6.20, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ATRI's P/E ratio is 64.50. In terms of profitability, HBIO's ROE is -0.73%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, HBIO is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ATRI's competition here
HBIO vs ANGO Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ANGO has a market cap of 493.3M. Regarding current trading prices, HBIO is priced at $6.20, while ANGO trades at $11.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ANGO's P/E ratio is -15.71. In terms of profitability, HBIO's ROE is -0.73%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, HBIO is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ANGO's competition here
HBIO vs OSUR Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, OSUR has a market cap of 278.1M. Regarding current trading prices, HBIO is priced at $6.20, while OSUR trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas OSUR's P/E ratio is -3.85. In terms of profitability, HBIO's ROE is -0.73%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, HBIO is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check OSUR's competition here
HBIO vs UTMD Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, UTMD has a market cap of 215.4M. Regarding current trading prices, HBIO is priced at $6.20, while UTMD trades at $67.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas UTMD's P/E ratio is 20.01. In terms of profitability, HBIO's ROE is -0.73%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, HBIO is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check UTMD's competition here
HBIO vs PDEX Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, PDEX has a market cap of 208.2M. Regarding current trading prices, HBIO is priced at $6.20, while PDEX trades at $65.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas PDEX's P/E ratio is 17.96. In terms of profitability, HBIO's ROE is -0.73%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, HBIO is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check PDEX's competition here
HBIO vs SMTI Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, SMTI has a market cap of 205.6M. Regarding current trading prices, HBIO is priced at $6.20, while SMTI trades at $22.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas SMTI's P/E ratio is 374.00. In terms of profitability, HBIO's ROE is -0.73%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, HBIO is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check SMTI's competition here
HBIO vs INFU Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, INFU has a market cap of 186.5M. Regarding current trading prices, HBIO is priced at $6.20, while INFU trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas INFU's P/E ratio is 24.97. In terms of profitability, HBIO's ROE is -0.73%, compared to INFU's ROE of +0.14%. Regarding short-term risk, HBIO is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check INFU's competition here
HBIO vs KRMD Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, KRMD has a market cap of 180.5M. Regarding current trading prices, HBIO is priced at $6.20, while KRMD trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas KRMD's P/E ratio is -78.60. In terms of profitability, HBIO's ROE is -0.73%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, HBIO is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check KRMD's competition here
HBIO vs STXS Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, STXS has a market cap of 173.5M. Regarding current trading prices, HBIO is priced at $6.20, while STXS trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas STXS's P/E ratio is -7.40. In terms of profitability, HBIO's ROE is -0.73%, compared to STXS's ROE of -1.53%. Regarding short-term risk, HBIO is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check STXS's competition here
HBIO vs MBOT Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, MBOT has a market cap of 83.8M. Regarding current trading prices, HBIO is priced at $6.20, while MBOT trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas MBOT's P/E ratio is -7.08. In terms of profitability, HBIO's ROE is -0.73%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, HBIO is more volatile compared to MBOT. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check MBOT's competition here
HBIO vs AKYA Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, HBIO is priced at $6.20, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas AKYA's P/E ratio is -1.34. In terms of profitability, HBIO's ROE is -0.73%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, HBIO is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check AKYA's competition here
HBIO vs ZTEK Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ZTEK has a market cap of 55.7M. Regarding current trading prices, HBIO is priced at $6.20, while ZTEK trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ZTEK's P/E ratio is -8.63. In terms of profitability, HBIO's ROE is -0.73%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, HBIO is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check ZTEK's competition here
HBIO vs DXR Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, DXR has a market cap of 55.6M. Regarding current trading prices, HBIO is priced at $6.20, while DXR trades at $10.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas DXR's P/E ratio is 6.73. In terms of profitability, HBIO's ROE is -0.73%, compared to DXR's ROE of +0.22%. Regarding short-term risk, HBIO is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check DXR's competition here
HBIO vs NYXH Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, NYXH has a market cap of 52.3M. Regarding current trading prices, HBIO is priced at $6.20, while NYXH trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas NYXH's P/E ratio is -0.56. In terms of profitability, HBIO's ROE is -0.73%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, HBIO is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check NYXH's competition here
HBIO vs STSS Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, STSS has a market cap of 51.2M. Regarding current trading prices, HBIO is priced at $6.20, while STSS trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas STSS's P/E ratio is -0.02. In terms of profitability, HBIO's ROE is -0.73%, compared to STSS's ROE of -1.66%. Regarding short-term risk, HBIO is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check STSS's competition here
HBIO vs OMIC Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, HBIO is priced at $6.20, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas OMIC's P/E ratio is -0.58. In terms of profitability, HBIO's ROE is -0.73%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, HBIO is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check OMIC's competition here
HBIO vs IGAP Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, HBIO is priced at $6.20, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas IGAP's P/E ratio is -10.52. In terms of profitability, HBIO's ROE is -0.73%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, HBIO is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check IGAP's competition here
HBIO vs POCI Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, POCI has a market cap of 44.8M. Regarding current trading prices, HBIO is priced at $6.20, while POCI trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas POCI's P/E ratio is -9.06. In terms of profitability, HBIO's ROE is -0.73%, compared to POCI's ROE of -0.37%. Regarding short-term risk, HBIO is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check POCI's competition here
HBIO vs NEPH Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, NEPH has a market cap of 37.1M. Regarding current trading prices, HBIO is priced at $6.20, while NEPH trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas NEPH's P/E ratio is 48.86. In terms of profitability, HBIO's ROE is -0.73%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, HBIO is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check NEPH's competition here
HBIO vs MLSS Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, MLSS has a market cap of 36.6M. Regarding current trading prices, HBIO is priced at $6.20, while MLSS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas MLSS's P/E ratio is -6.92. In terms of profitability, HBIO's ROE is -0.73%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, HBIO is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check MLSS's competition here
HBIO vs SDC Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, HBIO is priced at $6.20, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas SDC's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to SDC's ROE of -1.96%. Regarding short-term risk, HBIO is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check SDC's competition here
HBIO vs EKSO Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, HBIO is priced at $6.20, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas EKSO's P/E ratio is -2.31. In terms of profitability, HBIO's ROE is -0.73%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, HBIO is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check EKSO's competition here
HBIO vs IVC Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, HBIO is priced at $6.20, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas IVC's P/E ratio is -0.79. In terms of profitability, HBIO's ROE is -0.73%, compared to IVC's ROE of -0.46%. Regarding short-term risk, HBIO is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check IVC's competition here
HBIO vs RVP Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, HBIO is priced at $6.20, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas RVP's P/E ratio is -3.09. In terms of profitability, HBIO's ROE is -0.73%, compared to RVP's ROE of -0.08%. Regarding short-term risk, HBIO is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check RVP's competition here
HBIO vs ZJYL Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ZJYL has a market cap of 19.3M. Regarding current trading prices, HBIO is priced at $6.20, while ZJYL trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ZJYL's P/E ratio is 12.35. In terms of profitability, HBIO's ROE is -0.73%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, HBIO is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check ZJYL's competition here
HBIO vs FEMY Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, FEMY has a market cap of 9M. Regarding current trading prices, HBIO is priced at $6.20, while FEMY trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas FEMY's P/E ratio is -1.28. In terms of profitability, HBIO's ROE is -0.73%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, HBIO is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check FEMY's competition here
HBIO vs RGNT Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, RGNT has a market cap of 5.2M. Regarding current trading prices, HBIO is priced at $6.20, while RGNT trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas RGNT's P/E ratio is -0.06. In terms of profitability, HBIO's ROE is -0.73%, compared to RGNT's ROE of N/A. Regarding short-term risk, HBIO is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check RGNT's competition here
HBIO vs NXGL Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, NXGL has a market cap of 5.1M. Regarding current trading prices, HBIO is priced at $6.20, while NXGL trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas NXGL's P/E ratio is -1.40. In terms of profitability, HBIO's ROE is -0.73%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, HBIO is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check NXGL's competition here
HBIO vs NSTG Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, HBIO is priced at $6.20, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas NSTG's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, HBIO is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check NSTG's competition here
HBIO vs LUCY Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, LUCY has a market cap of 3.6M. Regarding current trading prices, HBIO is priced at $6.20, while LUCY trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas LUCY's P/E ratio is -0.58. In terms of profitability, HBIO's ROE is -0.73%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, HBIO is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check LUCY's competition here
HBIO vs POAI Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, HBIO is priced at $6.20, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas POAI's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to POAI's ROE of -107.05%. Regarding short-term risk, HBIO is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check POAI's competition here
HBIO vs NXGLW Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, NXGLW has a market cap of 2.9M. Regarding current trading prices, HBIO is priced at $6.20, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, HBIO is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check NXGLW's competition here
HBIO vs MHUA Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, HBIO is priced at $6.20, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas MHUA's P/E ratio is 0.25. In terms of profitability, HBIO's ROE is -0.73%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, HBIO is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check MHUA's competition here
HBIO vs GMVD Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, HBIO is priced at $6.20, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas GMVD's P/E ratio is -0.01. In terms of profitability, HBIO's ROE is -0.73%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, HBIO is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check GMVD's competition here
HBIO vs GMVDW Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, HBIO is priced at $6.20, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas GMVDW's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.73%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, HBIO is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check GMVDW's competition here
HBIO vs AVGR Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, HBIO is priced at $6.20, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas AVGR's P/E ratio is -0.05. In terms of profitability, HBIO's ROE is -0.73%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, HBIO is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check AVGR's competition here
HBIO vs STSSW Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, HBIO is priced at $6.20, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas STSSW's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to STSSW's ROE of +0.12%. Regarding short-term risk, HBIO is more volatile compared to STSSW. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check STSSW's competition here
HBIO vs GCTK Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, GCTK has a market cap of 350.2K. Regarding current trading prices, HBIO is priced at $6.20, while GCTK trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas GCTK's P/E ratio is 0.10. In terms of profitability, HBIO's ROE is -0.73%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, HBIO is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check GCTK's competition here
HBIO vs LUCYW Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, HBIO is priced at $6.20, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas LUCYW's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.73%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, HBIO is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check LUCYW's competition here
HBIO vs WOK Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, WOK has a market cap of 504. Regarding current trading prices, HBIO is priced at $6.20, while WOK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas WOK's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.73%, compared to WOK's ROE of -0.07%. Regarding short-term risk, HBIO is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for HBIO.Check WOK's competition here
HBIO vs APR Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, APR has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.20, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas APR's P/E ratio is 22.59. In terms of profitability, HBIO's ROE is -0.73%, compared to APR's ROE of +9.81%. Regarding short-term risk, HBIO is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check APR's competition here
HBIO vs ATRS Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.20, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ATRS's P/E ratio is 14.95. In terms of profitability, HBIO's ROE is -0.73%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, HBIO is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ATRS's competition here
HBIO vs ARTC Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ARTC has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.20, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ARTC's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.73%, compared to ARTC's ROE of N/A. Regarding short-term risk, HBIO is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ARTC's competition here
HBIO vs HRC Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, HRC has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.20, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas HRC's P/E ratio is 41.92. In terms of profitability, HBIO's ROE is -0.73%, compared to HRC's ROE of +0.14%. Regarding short-term risk, HBIO is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check HRC's competition here
HBIO vs IIN Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, IIN has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.20, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas IIN's P/E ratio is 226.45. In terms of profitability, HBIO's ROE is -0.73%, compared to IIN's ROE of -0.00%. Regarding short-term risk, HBIO is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check IIN's competition here
HBIO vs ALOG Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.20, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas ALOG's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.73%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, HBIO is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check ALOG's competition here
HBIO vs IVTY Comparison June 2026
HBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.9M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.20, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -2.88, whereas IVTY's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.73%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, HBIO is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for HBIO.Check IVTY's competition here